Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
H2A.Q variant histone 1, pseudogene (H2AQ1P), is a pseudogene member of the H2A histone variant family, specifically classified within the short H2A (sH2A) subgroup of histone variants[1][5][9]. H2A.Q is encoded by a single pseudogene in the human genome and lacks expression in human and primate tissues[1][9]. Unlike other functional histone variants, H2A.Q is only transcribed in the testis of some non-primate mammals (such as dogs and pigs) and is not thought to play any critical or active role in human biology[1]. As a pseudogene, it does not produce a functional protein and is not considered a therapeutic target, nor does it have any known involvement in disease, function, or interaction with drugs. Therefore, the entry is "incorrect" as a therapeutic target or relevant receptor in human biomedical research[1][9][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on H2A.Q variant histone 1, pseudogene (H2AQ1P).